← Eichor
Study identifier: NCT06539624 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease

Condition: Fabry Disease  ·  Sponsor: The Children's Hospital of Zhejiang University School of Medicine

PhaseNA
Planned participants12
Who can joinAll sexes, 7 Years to no upper limit
Healthy volunteersNo

About this study

Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease

This description comes directly from the study's public registry record.

Talk to the study team

Jianhua Mao, PhD  ·  13516819071  ·  maojh88@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Shanghai Children's Medical CenterShanghai, Shanghai Municipality, ChinaRecruiting
Children's Hospital, Zhejiang University School of MedicineHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06539624